Therapeutic potential of 5-HT2C receptor antagonists in the treatment of anxiety disorders. Wood, Martyn D Current drug targets. CNS and neurological disorders, 2: 383-7 (2003)
2003
Show Abstract
Anxiety disorders are the most common psychiatric illness affecting both adults and children. Following the observation that m-chlorophenylpiperazine(mCPP) induced anxiety-like states in patients and in animal models, it was shown that in man, mCPP behaves as a functionally selective agonist at the 5-hydroxytryptamine (5-HT)2C receptor. This caused much interest in the development of antagonists at the 5-HT2C receptor for the treatment of anxiety disorders. This review examines the pre-clinical and clinical evidence for a role of the 5-HT2C receptor in anxiety and evaluates the progress of compounds that target this therapeutic approach. | 14683466
 |